PT - JOURNAL ARTICLE AU - María Eugenia Toledo-Romani AU - Mayra García-Carmenate AU - Leslyhana Verdecia-Sánchez AU - Suzel Pérez-Rodríguez AU - Meybis Rodriguez-González AU - Carmen Valenzuela-Silva AU - Beatriz Paredes-Moreno AU - Belinda Sanchez-Ramirez AU - Raúl González-Mugica AU - Tays Hernández-Garcia AU - Ivette Orosa-Vázquez AU - Marianniz Díaz-Hernández AU - María Teresa Pérez-Guevara AU - Juliet Enriquez-Puertas AU - Enrique Noa-Romero AU - Ariel Palenzuela-Diaz AU - Gerardo Baro-Roman AU - Ivis Mendoza-Hernández AU - Yaima Muñoz AU - Yanet Gómez-Maceo AU - Bertha Leysi Santos-Vega AU - Sonsire Fernandez-Castillo AU - Yanet Climent-Ruiz AU - Laura Rodríguez-Noda AU - Darielys Santana-Mederos AU - Yanelda García-Vega AU - Guang Wu-Chen AU - Delaram Doroud AU - Alireza Biglari AU - Tammy Boggiano-Ayo AU - Yury Valdés-Balbín AU - Daniel García-Rivera AU - Dagmar García-Rivera AU - Vicente Vérez-Bencomo AU - SOBERANA Research Group TI - Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial AID - 10.1101/2022.01.01.21268271 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.01.21268271 4099 - http://medrxiv.org/content/early/2022/01/05/2022.01.01.21268271.short 4100 - http://medrxiv.org/content/early/2022/01/05/2022.01.01.21268271.full AB - Background We report results of immunogenicity, safety and reactogenicity of SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial.Method This phase IIb trial was designed as parallel, multicentre, adaptive, double blind, randomized and placebo-controlled. Subjects (N=810) aged 19-80 years were randomized to receive two doses of the recombinant SARS CoV-2 receptor binding domain (RBD) conjugated to tetanus toxoid (SOBERANA 02) and a third dose of dimeric RBD (SOBERANA Plus) 28 days apart; two production batches of active ingredient of SOBERANA 02 were evaluated. Primary outcome was the percentage of seroconverted subjects with ≥4-fold the anti-RBD IgG concentration. Secondary outcomes were safety, reactogenicity and neutralizing antibodies.Results Seroconversion rate in vaccinees was respectively 76.3 and 96.8% after two or three doses, compared with 7.3% in placebo group. Anti-RBD IgG increased significantly after first and second dose of SOBERANA 02 respect to placebo group; and the third dose with SOBERANA Plus boosts the response compared to the second dose. Neutralizing IgG antibodies were detected against D614G and VOCs α, β and δ. Specific and functional antibodies were detected at least until 7-8 months after the third dose. The frequency of serious adverse events (AEs) associated with vaccination was very low (0.1%); with only one serious AE consistent with vaccination. Local pain was the most frequent AE.Conclusions Two doses of SOBERANA 02 were well tolerated, safe an immunogenic in adults aged 19-80 years old. The heterologous combination with a third dose of SOBERANA Plus increased neutralizing antibodies, detectable 7-8 months after finishing the vaccination schedule.Trial registry https://rpcec.sld.cu/trials/RPCEC00000347Competing Interest StatementAuthors M.E.T.R., M.G.C., L.V.S., S.P.R, C.V.S, M.T.P.G., J.E.P, E.N.R., A.P.D., G.B.R., I.M.H., Y.M, Y.G.M., B.L.S.V., G.W.C., D.D., A.B., and D.G.R., declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Authors M.R.G., B.P.M., B.S.R., R.G.M., T.H.G., I.O.V., M.D.H., S.F.C., Y.C.R, L.R.N., D.S.M., Y.G.V., T.B.A., Y.V.B., D.G.R., and V.V.B., work at Finlay Vaccine Institute or the Centre of Molecular Immunology, institutions that develop and manufacture the vaccine candidates but they have not received an honorarium for this paper. B.S.R., S.F.C., Y.C.R, L.R.N., D.S.M., Y.V.B., D.G.R., D.G.R. and V.V.B., have filed patent applications related to the vaccine SOBERANA 02.Clinical Trialinternational clinical trial register. https://rpcec.sld.cu/trials/RPCEC00000347Funding StatementThis work was supported by the Finlay Vaccine Institute, BioCubaFarma and the Fondo Nacional de Ciencia y Tecnica (FONCI-CITMA-Cuba, contract 2020-20)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ad hoc centralized Research Ethics Committee from the Medical Sciences University, Faculty of Medicine Manuel Fajardo, Havana, designed by the Health Innovation Committee from the Cuban Ministry of Health (MINSAP)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors